Syndax Pharmaceuticals (SNDX) Research & Development (2015 - 2026)
Syndax Pharmaceuticals (SNDX) posted quarterly Research & Development of $58.8 million for Q1 2026, down 4.53% year-over-year from $61.6 million in Q1 2025, and down 25.17% quarter-over-quarter from $78.6 million in Q4 2025.
Syndax Pharmaceuticals (SNDX) Research & Development (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Research & Development history runs 12 years deep, the most recent figure standing at $58.8 million for Q1 2026.
- In Q1 2026, Research & Development fell 4.53% year-over-year to $58.8 million; the TTM figure through Mar 2026 stood at $256.0 million (up 34.15% YoY), while the FY2025 annual figure was $258.8 million, up 7.09% from the prior year.
- Research & Development for Q1 2026 stood at $58.8 million, down from $78.6 million in the prior quarter.
- The five-year high for Research & Development was $78.6 million in Q4 2025, with the low at $15.0 million in Q3 2024.
- The 5-year median for Research & Development is $48.7 million (2024), against an average of $45.4 million.
- The sharpest annual moves came in 2024 and 2025: Research & Development slumped 61.62% in 2024, then soared 275.2% in 2025.
- Syndax Pharmaceuticals' Research & Development stood at $31.8 million in 2022, then jumped by 73.13% to $55.1 million in 2023, then climbed by 18.87% to $65.5 million in 2024, then rose by 20.01% to $78.6 million in 2025, then slipped by 25.17% to $58.8 million in 2026.
- Business Quant data shows SNDX's Research & Development at $58.8 million in Q1 2026, $78.6 million in Q4 2025, and $56.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Syndax Pharmaceuticals | 1.77 Bn | 1.22 Bn | 60.67 Mn | 68.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 68.04 Mn |
| Mar 31, 2026 | 58.85 Mn |
| Dec 31, 2025 | 78.64 Mn |
| Sep 30, 2025 | 56.28 Mn |
| Jun 30, 2025 | 62.23 Mn |
| Mar 31, 2025 | 61.64 Mn |
| Dec 31, 2024 | 65.53 Mn |
| Sep 30, 2024 | 15.00 Mn |
| Jun 30, 2024 | 48.66 Mn |
| Mar 31, 2024 | 56.49 Mn |
| Dec 31, 2023 | 55.13 Mn |
| Sep 30, 2023 | 39.09 Mn |
| Jun 30, 2023 | 34.76 Mn |
| Mar 31, 2023 | 34.05 Mn |
| Dec 31, 2022 | 31.84 Mn |
| Sep 30, 2022 | 26.90 Mn |
| Jun 30, 2022 | 16.00 Mn |
| Mar 31, 2022 | 30.02 Mn |
| Dec 31, 2021 | 23.90 Mn |
| Sep 30, 2021 | 25.61 Mn |